- Conditions
- Myeloproliferative Diseases
- Interventions
- Ruxolitinib, Lenalidomide, Prednisone
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2641–2664
of 22,555
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pneumococcal Infection
- Interventions
- V110, V114, mRNA-1273, Placebo for V110, Placebo for V114
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 850 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 42
- States / cities
- North Hollywood, California • Northridge, California • Paramount, California + 38 more
- Conditions
- Traumatic Brain Injury
- Interventions
- Armodafinil, Placebo
- Drug · Other
- Lead sponsor
- Cephalon, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 53 more
- Conditions
- Hypertension
- Interventions
- Eplerenone
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 6 Years to 16 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 28
- States / cities
- Little Rock, Arkansas • Beverly Hills, California • Inglewood, California + 25 more
- Conditions
- B-cell Malignancies
- Interventions
- AZD5492
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 10
- States / cities
- La Jolla, California • Boston, Massachusetts • Rochester, Minnesota + 6 more
- Conditions
- Pediatric Cancer, Surgery
- Interventions
- ARISE with AR, ARISE without AR
- Device
- Lead sponsor
- ALTality, Inc.
- Industry
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Locally Advanced Esophageal or GE Junction Cancer
- Interventions
- AT-101
- Drug
- Lead sponsor
- Ascenta Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cervical Esophagus Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Gastroesophageal Junction Adenocarcinoma, Pathologic Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Thoracic Esophagus Adenocarcinoma
- Interventions
- Capecitabine, Carboplatin, Docetaxel, Fluorouracil, Hafnium Oxide-containing Nanoparticles NBTXR3, Intensity-Modulated Radiation Therapy, Leucovorin, Oxaliplatin, Paclitaxel
- Drug · Other · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Dyslipidemia, Hypertension
- Interventions
- Amlodipine besylate, Amlodipine besylate/atorvastatin calcium single pill combination
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Garden Grove, California + 44 more
- Conditions
- Childhood CNS Primitive Neuroectodermal Tumor
- Interventions
- Antineoplaston therapy (Atengenal + Astugenal)
- Drug
- Lead sponsor
- Burzynski Research Institute
- Other
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2005
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pregnancy, Obstetric Labor, Parturition
- Interventions
- fetal STAN monitor
- Device
- Lead sponsor
- The George Washington University Biostatistics Center
- Other
- Eligibility
- Female only
- Enrollment
- 11,108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2014
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 10 more
- Conditions
- Parkinson Disease
- Interventions
- THN102 Dosage A, THN102 Dosage B, THN102 Dosage C
- Drug
- Lead sponsor
- Theranexus
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 3
- States / cities
- Kansas City, Kansas • Boston, Massachusetts • Houston, Texas
- Conditions
- End-stage Renal Disease, Prevention of Thromboembolic Events, Hemodialysis, Hemodiafiltration
- Interventions
- BAY1213790 (Osocimab), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 704 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 26
- States / cities
- Azusa, California • Brawley, California • Encino, California + 21 more
- Conditions
- Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Interventions
- PF-07985045, Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, Sasanlimab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, PF-07284892
- Drug · Combination Product
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 12
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 6 more
- Conditions
- Congenital Bleeding Disorder, Haemophilia A
- Interventions
- turoctocog alfa
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 6 Months to 70 Years · Male only
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Long Beach, California • Tampa, Florida + 10 more
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Interventions
- Neladalkib (NVL-655), Midazolam, Repaglinide, Itraconazole
- Drug
- Lead sponsor
- Nuvalent Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 21
- States / cities
- Orange, California • Sacramento, California • Stanford, California + 16 more
- Conditions
- Pain
- Interventions
- bupivacaine liposome injectable suspension, Placebo
- Drug
- Lead sponsor
- Pacira Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 14
- States / cities
- Mobile, Alabama • Englewood, Colorado • Miami, Florida + 9 more
- Conditions
- Advanced Parkinson's Disease
- Interventions
- Rotigotine, Placebo
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Fountain Valley, California + 23 more
- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2026
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 10 more
- Conditions
- Endometrial Cancer
- Interventions
- conjugated estrogens
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 2,108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 149
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 99 more
- Conditions
- Advanced Solid Tumor
- Interventions
- Erdafitinib
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • Colorado Springs, Colorado • Hollywood, Florida + 22 more
- Conditions
- Neuropathy
- Interventions
- pregabalin, placebo
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Los Angeles, California • North Hollywood, California + 15 more
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease
- Interventions
- LIQ861
- Drug
- Lead sponsor
- Liquidia Technologies, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Fresno, California • Los Angeles, California + 15 more
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Bendamustine, Rituximab, Ibrutinib, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 523 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 44
- States / cities
- Tucson, Arizona • Burbank, California • La Jolla, California + 41 more